{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:24:26Z","timestamp":1767651866308,"version":"3.37.3"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":836,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.vhri.2014.07.008","type":"journal-article","created":{"date-parts":[[2014,9,30]],"date-time":"2014-09-30T17:48:07Z","timestamp":1412099287000},"page":"100-106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis"],"prefix":"10.1016","volume":"4","author":[{"given":"Kl\u00e1ra","family":"Kruntor\u00e1dov\u00e1","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"Klime\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"\u0160edov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji\u0159\u00ed","family":"\u0160tolfa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom\u00e1\u0161","family":"Dole\u017eal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Pet\u0159\u00edkov\u00e1","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2014.07.008_bib1","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/rheumatology\/ker374","article-title":"Economic studies in rheumatology: data, perspectives, challenges: their role in decision making","volume":"51","author":"Kobelt","year":"2012","journal-title":"Rheumatology"},{"issue":"Suppl. 1","key":"10.1016\/j.vhri.2014.07.008_bib2","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1007\/s10067-010-1637-6","article-title":"The economic burden of rheumatoid arthritis: beyond health care costs","volume":"30","author":"Zhang","year":"2011","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.berh.2011.10.001","article-title":"Economic consequences and potential benefits","volume":"25","author":"Fautrel","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/rheumatology\/keq323","article-title":"Rheumatology and work: a call for submissions","volume":"49","author":"Jones","year":"2010","journal-title":"Rheumatology"},{"issue":"Suppl. 11","key":"10.1016\/j.vhri.2014.07.008_bib5","doi-asserted-by":"crossref","first-page":"S337","DOI":"10.1002\/acr.20633","volume":"63","author":"Tang","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vhri.2014.07.008_bib6","first-page":"1","article-title":"Worker participation in rheumatic disease: the socioeconomic perspective","volume":"3","author":"Boonen","year":"2009","journal-title":"Arthritis Res Campaign"},{"issue":"Suppl. 31","key":"10.1016\/j.vhri.2014.07.008_bib7","first-page":"S71","article-title":"Work disability in early rheumatoid arthritis","volume":"21","author":"Sokka","year":"2003","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/03009740601061126","article-title":"Health economic issues in rheumatoid arthritis","volume":"35","author":"Kobelt","year":"2006","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib9","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3109\/03009740903544212","article-title":"Incidence and prevalence of psoriatic arthritis, ankylosing spondylitis, and reactive arthritis in the first descriptive population-based study in the Czech Republic","volume":"39","author":"Hanova","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib10","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1874312901105010091","article-title":"Prevalence of rheumatoid arthritis in the southern part of Denmark","volume":"5","author":"Pedersen","year":"2011","journal-title":"Open Rheumatol J"},{"issue":"Suppl.","key":"10.1016\/j.vhri.2014.07.008_bib11","first-page":"4","article-title":"The burden of ankylosing spondylitis","volume":"78","author":"Boonen","year":"2006","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib12","first-page":"Spec No.:5","article-title":"Social and economic impact of inflammatory arthritis","author":"Bergman","year":"2006","journal-title":"Postgrad Med"},{"key":"10.1016\/j.vhri.2014.07.008_bib13","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1136\/ard.2005.046367","article-title":"Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany","volume":"65","author":"Huscher","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib14","first-page":"267","article-title":"Health technology assessment (HTA) v principech a z\u00e1sad\u00e1ch posuzov\u00e1n\u00ed stupn\u011b z\u00e1vislosti","volume":"5","author":"\u010celedov\u00e1","year":"2012","journal-title":"Prakt Lek"},{"key":"10.1016\/j.vhri.2014.07.008_bib15","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/rheumatology\/keq399","article-title":"Quantifying the economic burden of productivity loss in rheumatoid arthritis","volume":"50","author":"Filipovic","year":"2011","journal-title":"Rheumatology"},{"key":"10.1016\/j.vhri.2014.07.008_bib16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2165\/11588380-000000000-00000","article-title":"Cost-of-illness studies: a guide to critical evaluation","volume":"29","author":"Largand","year":"2011","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.07.008_bib17","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.berh.2012.08.008","article-title":"An update on the measurement of productivity losses due to rheumatoid diseases","volume":"26","author":"Zhang","year":"2012","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib18","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/acr.20011","article-title":"Reliability, validity, and responsiveness of five at-work productivity measures in patients with rheumatoid arthritis or osteoarthritis","volume":"62","author":"Beaton","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.vhri.2014.07.008_bib19","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jval.2011.07.009","article-title":"Development of a composite questionnaire, the valuation of lost productivity, to value productivity losses: application in rheumatoid arthritis","volume":"15","author":"Zhang","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.07.008_bib20","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/JOM.0b013e318218abf1","article-title":"Measuring time input loss among patients with rheumatoid arthritis: validity and reliability of the Valuation of Lost Productivity questionnaire","volume":"53","author":"Zhang","year":"2011","journal-title":"J Occup Environ Med"},{"key":"10.1016\/j.vhri.2014.07.008_bib21","doi-asserted-by":"crossref","first-page":"R140","DOI":"10.1186\/ar4602","article-title":"Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritis","volume":"16","author":"Osterhaus","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.vhri.2014.07.008_bib22","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/art.23825","article-title":"The need for standardization: a literature review of indirect costs of rheumatoid arthritis and osteoarthritis","volume":"59","author":"F","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.vhri.2014.07.008_bib23","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/j.1524-4733.2007.00288.x","article-title":"Difficulties in calculating productivity costs: work disability associated with borderline personality disorder","volume":"11","author":"van Asselt","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.07.008_bib24","unstructured":"Reilly Associates, Health Outcomes Research. Work Productivity and Activity Impairment Questionnaire. 2002. Available from: http:\/\/www.reillyassociates.net\/WPAI_SHP.html. [Accessed September 25, 2011]."},{"key":"10.1016\/j.vhri.2014.07.008_bib25","unstructured":"Stanford University School of Medicine Division of Immunology & Rheumatology (formerly called the PROMIS HAQ). The Health Assessment Questionnaire (HAQ)\u00a9 and the Improved HAQ \u00a9. 2009. Available from: http:\/\/aramis.stanford.edu\/downloads\/HAQ%20Instructions%20%28ARAMIS%29%206-30-09.pdf. [Accessed September 25, 2011]."},{"key":"10.1016\/j.vhri.2014.07.008_bib26","unstructured":"BASDAI. Bath Ankylosing Spondylitis Disease Activity Index. 2005. Available from: http:\/\/basdai.com. [Accessed September 25, 2011]."},{"key":"10.1016\/j.vhri.2014.07.008_bib27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00019053-200422040-00002","article-title":"A review of self-report instruments measuring health-related work productivity: a patient-reported outcomes perspective","volume":"22","author":"Prasad","year":"2004","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.07.008_bib28","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1093\/rheumatology\/kep457","article-title":"Validity, reliability and responsiveness of the Work Productivity and Activity Impairment Questionnaire in ankylosing spondylitis","volume":"49","author":"Reilly","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.vhri.2014.07.008_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3899\/jrheum.090242","article-title":"Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis","volume":"37","author":"Maksymowych","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib30","first-page":"73","article-title":"Assessment of functional ability in patients with rheumatoid arthritis: validation of the Czech version of the Stanford Health Assessment Questionnaire (HAQ) [in Czech]","volume":"18","author":"\u0160l\u00e9grov\u00e1","year":"2010","journal-title":"\u010ces Revmatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib31","first-page":"43","article-title":"Evaluation of status and quality of life in patients with ankylosing spondylitis\u2014validation of Czech versions of the questionnaires\u2014BAS-G","volume":"2","author":"\u0160l\u00e9glov\u00e1","year":"2004","journal-title":"BADAI and BASFI. \u010ces Revmatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/annrheumdis-2013-204573","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib33","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.2010.133132","article-title":"A decrease in disease activity score (DAS) level is associated with a decrease in health assessment questionnaire (HAQ) score, independent of follow-up duration, during 5 years of tightly controlled treatment: results from the BeSt study","volume":"70","author":"van der","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00403-010-1080-1","article-title":"Definition of treatment goals for moderate to severe psoriasis: a European consensus","volume":"303","author":"Mrowietz","year":"2011","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.vhri.2014.07.008_bib35","doi-asserted-by":"crossref","first-page":"460","DOI":"10.2165\/00019053-199610050-00003","article-title":"A practical guide for calculating indirect costs of disease","volume":"10","author":"Koopmanschap","year":"1996","journal-title":"Pharmacoeconomics"},{"issue":"Suppl. 1","key":"10.1016\/j.vhri.2014.07.008_bib36","doi-asserted-by":"crossref","first-page":"i89","DOI":"10.1136\/ard.2009.117150","article-title":"The value of productivity: human-capital versus friction-cost method","volume":"69","author":"van den Hout","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib37","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00019053-200523020-00002","article-title":"The friction-cost method: replacement for nothing and leisure for free?","volume":"23","author":"Brouwer","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.07.008_bib38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2165\/00019053-200523020-00001","article-title":"Friction-cost method as an alternative to the human-capital approach in calculating indirect costs","volume":"23","author":"Birnbaum","year":"2005","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.07.008_bib39","unstructured":"Czech Statistical Office. Average gross monthly wage. Available at: http:\/\/vdb.czso.cz\/vdbvo\/tabparam.jsp?voa=tabulka&cislotab=PRA1100CU&&kapitola_id=15. [Accessed September 25, 2011]."},{"key":"10.1016\/j.vhri.2014.07.008_bib40","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/ard.2004.033977","article-title":"Productivity costs among patients with rheumatoid arthritis: the influence of methods and sources to value loss of productivity","volume":"64","author":"Verstappen","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib41","first-page":"342","article-title":"Prevalence and predictors of reduced work productivity in patients with psoriatic arthritis","volume":"32","author":"Kennedy","year":"2014","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.vhri.2014.07.008_bib42","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000090654","article-title":"Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study","volume":"212","author":"Sohn","year":"2006","journal-title":"Dermatology"},{"key":"10.1016\/j.vhri.2014.07.008_bib43","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/TCRM.S2740","article-title":"Moderate and severe plaque psoriasis: cost-of-illness study in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.vhri.2014.07.008_bib44","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2165\/11591520-000000000-00000","article-title":"Lost productivity in four European countries among patients with rheumatic disorders: are absenteeism and presenteeism transferable?","volume":"30","author":"Knies","year":"2012","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vhri.2014.07.008_bib45","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/rheumatology\/ker371","article-title":"Productivity loss due to absenteeism and presenteeism by different instruments in patients with RA and subjects without RA","volume":"51","author":"Braakman-Jansen","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.vhri.2014.07.008_bib46","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.jval.2013.03.1624","article-title":"Compensation mechanisms for lost productivity: a comparison between four European countries","volume":"16","author":"Knies","year":"2013","journal-title":"Value Health"},{"key":"10.1016\/j.vhri.2014.07.008_bib47","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/kes074","article-title":"Two-year direct and indirect costs for patients with inflammatory rheumatic joint diseases: data from real-life follow-up of patients in the NOR-DMARD registry","volume":"51","author":"Kvamme","year":"2012","journal-title":"Rheumatology"},{"key":"10.1016\/j.vhri.2014.07.008_bib48","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","article-title":"Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register","volume":"49","author":"Verstappen","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.vhri.2014.07.008_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/1756-185x.12018","article-title":"Working life and physical activity in ankylosing spondylitis pre and post anti-tumor necrosis factor-alpha therapy","volume":"17","author":"Prince","year":"2014","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.vhri.2014.07.008_bib50","doi-asserted-by":"crossref","unstructured":"Kavanaugh A, Gladman D, van der Heijde D, et al. Improvements in productivity at paid work and within the household, and increased participation in daily activities after 24 weeks of certolizumab pegol treatment of patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-controlled study. Ann Rheum Dis. 2014. http:\/\/dx.doi.org\/10.1136\/annrheumdis-2014-205198. [Epub ahead of print]","DOI":"10.1136\/annrheumdis-2014-205198"},{"key":"10.1016\/j.vhri.2014.07.008_bib51","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2298\/VSP1402144K","article-title":"Cost-effectiveness analysis of tocilizumab in combination with methotrexate for rheumatoid arthritis: a Markov model based on data from Serbia, country in socioeconomic transition","volume":"71","author":"Kosti\u0107","year":"2014","journal-title":"Vojnosanit Pregl"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109914000624?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109914000624?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,28]],"date-time":"2018-09-28T18:52:00Z","timestamp":1538160720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109914000624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":51,"alternative-id":["S2212109914000624"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2014.07.008","relation":{},"ISSN":["2212-1099"],"issn-type":[{"type":"print","value":"2212-1099"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Work Productivity and Costs Related to Patients with Ankylosing Spondylitis, Rheumatoid Arthritis, and Psoriasis","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2014.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}